TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06033196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: The initial dose of tocilizumab will be administered in the operating room before reperfusion of the first lung during the lung transplant surgery.~6 doses will be given once every four weeks over a 20-week period. The dose is approved for pediatric patients who weigh 30 kg or more

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Tocilizumab
Description: Placebo 0.9% Sodium Chloride Injection USP (Normal Saline)~Placebo will be given as a single intravenous dose, volume matched to tocilizumab. Placebo will be administered over a period of approximately 60 minutes; once every four weeks over a 20-week period. The first placebo dose will be during the transplant surgery before reperfusion of the first lung allograft, with 5 subsequent monthly doses
Study: NCT06295107

Intervention type: DIAGNOSTIC_TEST
Intervention: Ankle Passive Range of Movement (pROM)
Description: Ankel and knee pROM measurements.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ankle Passive Range of Movement (pROM)
Description: Ankel and knee pROM measurements.

Intervention type: DIAGNOSTIC_TEST
Intervention: Knee Passive Range of Movement (pROM)
Description: Ankel and knee pROM measurements.

Intervention type: DIAGNOSTIC_TEST
Intervention: Knee Passive Range of Movement (pROM)
Description: Ankel and knee pROM measurements.
Study: NCT04135365

Intervention type: BEHAVIORAL
Intervention: neurocognitive assessment
Description: Observational study therefore there are no interventions

Intervention type: BEHAVIORAL
Intervention: neurocognitive assessment
Description: Observational study therefore there are no interventions

Intervention type: BEHAVIORAL
Intervention: neuroimaging assessment
Description: Observational study therefore there are no interventions

Intervention type: BEHAVIORAL
Intervention: neuroimaging assessment
Description: Observational study therefore there are no interventions
Study: NCT05251246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: recovery management program
Description: The recovery management program consists in training the nurses and physicians during a 15-day training course to optimize their recovery abilities : sleep management according to the schedules by anticipation and recovery, and stress management through cardio-feedback techniques (cardiac coherence) also called controlled breathing techniques and mental imagery.
Study: NCT06069531

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus johnsonii, Placebo Comparator: White pomegranate extract
Description: Group A: Placebo; Group B: heat-killed Lactobacillus johnsonii TCI250; Group C: White pomegranate extract, dosage of 500mg for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus johnsonii, Placebo Comparator: White pomegranate extract
Description: Group A: Placebo; Group B: heat-killed Lactobacillus johnsonii TCI250; Group C: White pomegranate extract, dosage of 500mg for 8 weeks.
Study: NCT05671094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Physical, mental, stress reducing and dietary prehabilitation programme, 4 to 2 weeks before surgery
Study: NCT04619654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with implantation of trifocal IOL combined with trabecular scaffold
Description: Cataract surgery with implantation of the PanOptix IOL combined with minimally invasive glaucoma surgery utilizing the Hydrus Microstent
Study: NCT05403658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Navigation
Description: FN will be delivered by navigators who will provide support and services that complement obesity management care provided by multidisciplinary teams at the study clinical sites. With advanced training in motivational interviewing and patient- / family-centered care, navigators will access a bundle of logistical and relational strategies to help families derive the greatest possible benefit from their care, which will include working to reduce barriers to care, improve access, and optimize treatment outcomes related to obesity management that is part of their Usual Care. Navigators will provide various resources/supports to study participants including, but not limited to, offering communication via text message, flexible navigator appointments, parking/transit passes, community-based resources, and liaising with members of the multidisciplinary clinical teams at each site.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual Care is delivered similarly across the 2 clinical sites. Obesity management is offered by multidisciplinary teams that include clinicians with advanced expertise in pediatrics, nutrition, mental health, physical activity/exercise, and behavior change. Interventions are tailored to families' readiness, capabilities, and motivation to make healthy lifestyle and behavioral changes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care is delivered similarly across the 2 clinical sites. Obesity management is offered by multidisciplinary teams that include clinicians with advanced expertise in pediatrics, nutrition, mental health, physical activity/exercise, and behavior change. Interventions are tailored to families' readiness, capabilities, and motivation to make healthy lifestyle and behavioral changes.
Study: NCT04993586

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0302-COVID19 for Intramuscular Injection
Description: Vaccination 2 mg of AG0302-COVID19 three times at 2-week intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0302-COVID19 for Intramuscular Injection
Description: Vaccination 4 mg of AG0302-COVID19 twice at 4-week intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0302-COVID19 for Intramuscular Injection
Description: Vaccination 8 mg of AG0302-COVID19 twice at 4-week intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0302-COVID19 for Intradermal Injection
Description: Vaccination 1 mg of AG0302-COVID19 three times at 2-week intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0302-COVID19 for Intradermal Injection
Description: Vaccination 1 mg of AG0302-COVID19 twice at 4-week intervals
Study: NCT05818124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
Study: NCT06098573

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information condition
Description: Participants in the DUIC Information condition will receive a Qualtrics link with six infographics created to educate about DUIC. Four infographics were retrieved from government websites, one was provided by a non-profit (i.e., Arrive Alive Drive Sober), and the research team created the final one. After reviewing each infographic, participants will respond to a few questions about the infographic. Questions asked to the DUIC Info Control will obtain data related to: seeing the infographic before, perceptions on the infographic content, aspects they liked/disliked, and likelihood to share with their peers. All items will be treated as research data.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No contact
Description: Participants in the passive control will receive no contact until the three and six-month follow-ups.
Study: NCT05185622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone
Description: Oral administration of vamorolone for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone
Description: Oral administration of vamorolone for 12 weeks.
Study: NCT06028113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE 2.0
Description: Overview of content and strategies: 1) Education on stage of development specific to infant feeding, sleep and infant regulation, attunement to cues; 2) Attunement to cues: reinforcing and modeling accurate discernment \& responsiveness to cues; 3) Infant Soothing and Regulation: Coaching alternative strategies for soothing that feeding for non-hungry, fussy infants; 4) Routines \& Strategies: Promoting developmental activities during wake windows and longer consolidated sleep at night as the infant grows.
Study: NCT05818124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo molnupiravir
Description: Four placebo capsules matched to molnupiravir taken twice daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo molnupiravir
Description: Four placebo capsules matched to molnupiravir taken twice daily by mouth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo molnupiravir
Description: Four placebo capsules matched to molnupiravir taken twice daily by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oseltamivir
Description: Placebo capsule matched to oseltamivir taken twice daily by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: One capsule of oseltamivir 75 mg taken twice daily by mouth.
Study: NCT05926050

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment (CopaPrime+ (USANA Health Sciences)
Description: Participants received and consumed 2 treatment tablets immediately following baseline testing, and one hour prior to post-treatment testing. Each tablet contained extracts of Bacopa monnieri (150 mg), Coffea arabica (50 mg), and Panax quinquefolius L. (50 mg)
Study: NCT05185622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone
Description: Oral administration of vamorolone for 12 weeks.
Study: NCT05818124

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A Virus
Description: Influenza A challenge virus given once by intranasal administration at an inoculum concentration of between approximately 5 and 7 Log10 tissue culture infective dose 50% (TCID50/mL).
Study: NCT05185622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone
Description: Oral administration of vamorolone for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone
Description: Oral administration of vamorolone for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone
Description: Oral administration of vamorolone for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone
Description: Oral administration of vamorolone for 12 weeks.
Study: NCT05286619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg will be administered on Day 1 every 3 weeks for up to 24months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin at 35 mg/m2 IV using a split dose regimen on Day 1 and Day 8 of each 3-week cycle, up to 6 cycles.
Study: NCT05926050

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received and consumed 2 placebo tablets immediately following baseline testing, and one hour prior to post-treatment testing. Each tablet contained microcrystalline cellulose. The size, shape and appearance of the placebo tablet was identical to the treatment tablet.
Study: NCT05286619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at AUC 5 IV on Day 1 of each 3-week cycle, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1250mg/m2 IV on Day 1 and Day 8 of each 3-week cycle, up to 6 cycles
Study: NCT05400564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up
Description: This intervention includes access to the Family Check-Up app and telehealth coaching provided by trained mental health providers. Parents can contact their Coach as often as they like and a minimum of 3 coaching sessions will be scheduled.
Study: NCT06560736

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Show Me FIRST coping skills intervention
Description: Show Me FIRST is a flexible, transdiagnostic intervention organized around well-tested principles of youth psychotherapeutic change.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Show Me FIRST coping skills intervention
Description: Show Me FIRST is a flexible, transdiagnostic intervention organized around well-tested principles of youth psychotherapeutic change.
Study: NCT04912518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine (DEX)
Description: The patient began to inject DEX intravenously as soon as he enrolled. This study started with the maximum maintenance dose allowed by the label (0.7μg/kg/h). With reference to previous studies, we set 3 pump injection gradients within the range of 0.2-0.7μg/kg/h (0.2μg/kg/h, 0.45μg/kg/h, 0.7μg/kg/h), and based on the patient's heart rate , systolic blood pressure and RASS sedation score to adjust.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: The patient began intravenous injection of normal saline immediately after enrollment. The administration method and dosage adjustment of normal saline are the same as DEX.
Study: NCT05040932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH004
Description: IV infusion once every 3 weeks (Q3W).
Study: NCT06643871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted physical activity program involving connected bikes
Description: The treatment being studied involves a program (DYNAMO-PSY) of adapted physical activity with an enriched environment (connected bike, visualized and experienced routes in virtual reality) and is supervised, comprising (on average) two sessions per week, a total of 20 sessions to be completed over a maximum of 15 weeks. Each session will last 60 minutes and will be supervised by a case manager. They will be composed of a warm up, session on the bike (around 30 minutes of bicycling) and stretching. They will take place in an adequate room in the clinical research department of Saint Anne Hospital. The usual hygienic-dietetic care is not modified by the study and consists of the care proposed to patients of the GHU Paris Psychiatry and Neuroscience who have had a first psychotic episode and are treated primarily with medication: clinical and biological monitoring, dietary consultations, therapeutic education group concerning diet and lifestyle.
Study: NCT05605249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cue X
Description: The Cue X movement training module includes several games that can be performed in someone's home environment. The games are designed based on known physiotherapy guidelines and evidence for improving motor symptoms for people with PD and delivered in AR. Some of the games also have integrated cueing to allow people with more severe mobility impairments to participate. Feedback of performance can be given using the movement data of the AR headsets.
Study: NCT05301127

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: spinal-epidural device
Description: received combined spinal-epidural-general anesthesia.
Study: NCT05702450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 Recombinant Humanized Monoclonal Antibody Injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CM310
Description: CM310 Recombinant Humanized Monoclonal Antibody Injection
Study: NCT06548438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral resection of the bladder performed with PDD tecnique and Hexvix
Description: For the execution of PDD cystoscopy in blue light, it is necessary to use the study drug (Hexvix) which, after intravesical instillation, causes an accumulation of porphyrins in the lesions of the bladder wall at the intracellular level. The intracellular porphyrins are photoactive fluorescent compounds that emit red light when excited with blue light. Consequently, the preneoplastic and neoplastic lesions will emit a red luminescence against a blue background, allowing for better visualisation and subsequent resection.
Study: NCT06194838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ossur Power Knee
Description: Newest version of the commercially-available powered knee developed by Ossur.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reboocon Intuy Knee
Description: Commercially-available powered knee developed by Reboocon.
Study: NCT05757050

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Re-Focus Verum Tablets
Description: The active intervention contains Scutellaria baicalensis (400 mg) and Crataegus (40 mg) and is in the form of a chewable tablet with a blood-orange flavour

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Re-Focus Verum Tablets
Description: The active intervention contains Scutellaria baicalensis (400 mg) and Crataegus (40 mg) and is in the form of a chewable tablet with a blood-orange flavour

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Re-Focus Placebo Tablets
Description: The placebo will be a matched control.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Re-Focus Placebo Tablets
Description: The placebo will be a matched control.
Study: NCT05102019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm 1: treatment with Neovasc Reducer
Description: Neovasc reducer is an implantable device being evaluated for the alleviation of refractory angina symptoms

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Arm 2 (control): Implantation procedure with no device implanted
Description: No device is implanted

Intervention type: DEVICE
Group type: OTHER
Intervention: Arm 3 (unblinded, non-randomized): Single arm registry
Description: Neovasc reducer is an implantable device being evaluated for the alleviation of refractory angina symptoms
Study: NCT05994846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RISES-T System
Description: The RISES-T system is a hardware and software platform that has been designed and developed to help people living with movement impairment due to Spinal Cord Injury (SCI) to improve and/or restore mobility. The hardware consists of a functional electrical stimulation device that delivers stimulation to the skin through surface electrodes; a series of wearable sensors that collect kinematic (IMU) data and muscle activity (EMG) data, and RISES Software, which incorporates algorithms that utilizes the streaming IMU and EMG sensor data to inform the electrical stimulation parameters and enables real-time visualization of the sensor data and stimulation parameters via Graphical User Interface (GUI).
Study: NCT05321108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A (GA)(Aerobic exercise group)
Description: Aerobic Exercise has been demonstrated to be a safe strategy to improve several health outcomes in Systemic lupus erythematosus (SLE)SLE, including depressive symptoms or, even more importantly, fatigue and quality of life.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B (GB) (Whole-body vibration (WBV) group)
Description: (WBV) has been growing over the years. WBVE occurs when the subject is in contact with the vibrating platform in operation and is exposed to the generated mechanical vibrations. WBV has a positive action on muscle strength, bone formation, balance, flexibility, functional capacity and fatigue.
Study: NCT05736471

Intervention type: DIAGNOSTIC_TEST
Intervention: Computational dissociation of the causes of cognitive rigidity in depression
Description: involves a single testing session with surveys and tasks relevant to the experiment involving behavioral tasks and self-report questions through an online crowd-sourcing platform
Study: NCT06351280

Intervention type: OTHER
Group type: OTHER
Intervention: Standardised Physiotherapy Plan
Description: Single session of coached deep breathing and coughing exercises. 10 supervised slow flow deep breaths to total lung capacity with a 3-5 second end inspiratory hold completed with 2 end inspiratory sniffs. 2-3 supported coughs or huffs. Repeated for another set. Patients instructed to perform independently hourly. Assisted ambulation according to the following protocol:~* Stage 1 of 2 minutes.~* Stage 2 of 0-1 minute.~* Stage 3 of 1 - 3 minutes.~* Stage 4 of 3 - 6 minutes.~* Stage 5 of 6 - 10 minutes.~* Stage 6 of 10 - 15 minutes.~* Stage 7 \> 15 minutes. Total session time is the accumulative work time.
Study: NCT05159128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-75105186
Description: JNJ-75105186 will be administered orally in Part 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-75105186
Description: JNJ-75105186 will be administered orally in Part 1 and 2.
Study: NCT05818124

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza A Virus
Description: Influenza A challenge virus given once by intranasal administration at an inoculum concentration of between approximately 5 and 7 Log10 tissue culture infective dose 50% (TCID50/mL).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Influenza A Virus
Description: Influenza A challenge virus given once by intranasal administration at an inoculum concentration of between approximately 5 and 7 Log10 tissue culture infective dose 50% (TCID50/mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A Virus
Description: Influenza A challenge virus given once by intranasal administration at an inoculum concentration of between approximately 5 and 7 Log10 tissue culture infective dose 50% (TCID50/mL).
Study: NCT05549063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobility and Stability Exercise
Description: Mobility and stability exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Exercise
Description: Balance and reaching exercise
Study: NCT05437172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injectable platelet rich fibrin with demineralized dentin graft
Description: after atraumatic extraction, collection of whole venous blood (9 ml) in sterile vacutainer tubes will be done without anticoagulant added, vacutainer tubes will be then placed in a centrifugal machine at 700 revolutions per minute (rpm) for 3 min with a tube filled with water to maintain the balance during the centrifuging process. ADDG particles prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralization then washed twice in saline and dried with sterile gauze. Graft particles will be loaded at the defect site to restore ridge form, large metal condenser was used to adapt the graft to the defect and stabilizing the graft with sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: demineralized dentin graft
Description: after atraumatic extraction, ADDG particles will be prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralization then washed twice in saline and dried with sterile gauze.~Graft particles will be loaded at the defect site to restore ridge form, large metal condenser was used to adapt the graft to the defect and stabilizing the graft with sutures.